Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Conditions

• B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
• Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
• CD22 Positive
• Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
• Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
• Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions

• DRUG: Bosutinib
• BIOLOGICAL: Inotuzumab Ozogamicin

Sponsor

M.D. Anderson Cancer Center

Collaborators

• [object Object]